Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4, which blocks the immunosuppressive interaction between CTLA-4 and its ligands on cells (CD80/CD86) to promote the activation and proliferation of T cells, and enhance anti-tumor immune function (33). The gene discussed is CTLA4; the disease is neoplasm.